Care, Research Biosimilars are FDA-approved drugs that are “highly similar” to an existing biologic drug. A common biologic used to treat HER2-positive breast cancer is trastuzumab (Herceptin®). There are several biosimilars to trastuzumab available to treat early and metastatic HER2-positive breast cancers. A few facts about biosimilars: Biosimilars are used to treat breast cancer and also for supportive care to manage side effects of cancer treatment.As the science behind breast cancer treatments advance, biosimilars are creating more treatment options.The FDA requires manufacturers to prove there are no “clinically meaningful” differences in the safety, purity and potency (strength) between their biosimilar and the original biologic drug. To learn more, visit biosimilars.komen.org page. << Previous Post Karen Sock Thought She Had... Komen Blog Read More Next Post >> An MBC Diagnosis and Job... Komen Blog Read More Related Stories Previous Next Komen Blog Breast Cancer, No Longer Your... Read More Komen Blog Komen LA’s Mark Pilon Recovering... Read More Komen Blog Tracey’s Mission: Educating Others Read More Komen Blog Communicating With Your Health Care... Read More Komen Blog Disney® Star Sends Mother’s Day... Read More Komen Blog Komen Raises Concerns About State’s... Read More Komen Blog An Update on Genetic Testing... Read More Komen Blog Komen Asks Congress for Policies... Read More Komen Blog 8 Ways to Help a... Read More Komen Blog In Case You Missed It... Read More Komen Blog 8 Questions to Ask Your... Read More Komen Blog Using Genomics to Predict a... Read More Komen Blog For Komen Scholar Barbara Segarra-Vazquez,... Read More Komen Blog I Am Healed Read More Komen Blog Role of Local and Systemic... Read More Komen Blog My Mom is a Fighter,... Read More Komen Blog Past Clinical Trials Pave The... Read More Amanda DeBard In Case You Missed It:... Read More